Compare BIO-TECHNE Corp (TECH) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs ProShares Ultra Semiconductors — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while ProShares Ultra Semiconductors trades at $89. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while ProShares Ultra Semiconductors pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, ProShares Ultra Semiconductors nearer its low. Which is the better fit depends on your goals.
| TECH | USD | |
|---|---|---|
Market Cap | $11.34B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $72.48 | $113.53 |
52-Week Low | $43.31 | $43.19 |
Enterprise Value | $11.36B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
USD stock trades at $89.70, up 1.01% with bullish technical signals from moving averages. The company announced a dividend of $0.14 per share scheduled for June 2026. Technical indicators show strong support at $88 and resistance at $92, with RSI levels in neutral territory suggesting balanced momentum.
The stock shows technical strength but lacks current fundamental data for comprehensive valuation. The upcoming dividend provides income appeal, though investors face uncertainty without recent financial metrics. Market sentiment appears cautiously optimistic given the technical setup and corporate action.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
